WO2001012579A2 - New stilbenes with vascular damaging activity - Google Patents

New stilbenes with vascular damaging activity Download PDF

Info

Publication number
WO2001012579A2
WO2001012579A2 PCT/GB2000/003067 GB0003067W WO0112579A2 WO 2001012579 A2 WO2001012579 A2 WO 2001012579A2 GB 0003067 W GB0003067 W GB 0003067W WO 0112579 A2 WO0112579 A2 WO 0112579A2
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
cis
stilbene
formula
alkyl
Prior art date
Application number
PCT/GB2000/003067
Other languages
English (en)
French (fr)
Other versions
WO2001012579A3 (en
Inventor
Peter David Davis
Original Assignee
Angiogene Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharmaceuticals Ltd. filed Critical Angiogene Pharmaceuticals Ltd.
Priority to NZ517069A priority Critical patent/NZ517069A/en
Priority to AU64581/00A priority patent/AU779980B2/en
Priority to JP2001516880A priority patent/JP2003507356A/ja
Priority to CA002379544A priority patent/CA2379544A1/en
Priority to EP00951727A priority patent/EP1206429A2/en
Publication of WO2001012579A2 publication Critical patent/WO2001012579A2/en
Publication of WO2001012579A3 publication Critical patent/WO2001012579A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/12Esters of phosphoric acids with hydroxyaryl compounds

Definitions

  • Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of rheumatoid arthritis patients and of atherosclerotic plaques
  • Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy In all these diseases reversal of neovascularisation by damaging the newly-formed vascular endothelium is expected to have a beneficial therapeutic effect
  • tumour vasculature has several important advantages over a direct attack on the tumour
  • the endothelial cells of tumour vasculature are more genetically stable than those of the tumour itself and are therefore less likely to become resistant to the damaging agent
  • vascular damaging agents are able to attack a wide range of tumour types
  • tubulin-binding agents including the stilbenes combretastatin Al, combretastatin A4 (D J Chaplin et al , British J Cancer 27, S86-S88 (1996))and combretastatin A4 phosphate (D J Chaplin et al , Anticancer Research 19, 189-196, (1999)) are known to selectively damage neovasculature of solid tumours in animal models.
  • vascular-damaging stilbenes combretastatin Al, combretastatin A4 and combretastatin A4 phosphate have a 4-methoxy group in the "B" ring.
  • the compounds of the invention lack a 4-methoxy group in the ring corresponding to the "B" ring of combretastatin A4.
  • substituting alternative groups for the 4-methoxy group in the B-ring of combretastatin A4 would considerably reduce biological activity:
  • Woods et al. disclose analogues of combretastatin with reduced potency.
  • the 4-methyl compound shows 3.5 to 36-fold reduction in potency against four cell lines compared to the 4-methoxy compound.
  • R',R 2 and R 3 are each independently alkyl
  • R 4 is alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo
  • R 5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxy or halo, and the pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof.
  • alkyl alone or in combinations, means a straight or branched-chain alkyl group containing from one to seven, preferably a maximum of four, carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl and pentyl.
  • alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy and t-butoxy.
  • halogen means fluorine, chlorine, bromine or iodine.
  • An alkenyl group may be for example an olefinic group containing from two to seven carbon atoms for example methylene, ethylene, n-propylene, i-propylene, n-butylene, i- butylene, s-butylene and t-butylene.
  • An alkynyl group may be for example an ethynyl , propynyl or butynyl group.
  • salts include pharmaceutically acceptable salts for example acid addition salts including hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates and tartrates, salts derived from inorganic bases including alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and salts derived from organic amines such as morpholine, piperidine or dimethylamine salts.
  • acid addition salts including hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates and tartrates
  • salts derived from inorganic bases including alkali metal salt
  • Prodrugs of the invention are compounds which upon administration to a mammal produce compounds of formula (1). Such prodrugs can be for example converted within the mammal by hydrolysis. Prodrugs are preferably ester derivatives of the phenolic hydroxy group contained in compounds of formula (1) such as, for example, phosphate esters, carboxylate esters, sulphate esters and carbonates.
  • Preferred compounds of the invention are those of formula 1 in which R 1 , R 2 and R 3 are all methyl, and prodrugs thereof Further preferred compounds of the invention are those of formula 1 in which R 1 , R 2 and R 3 are all methyl and R 5 is hydrogen and prodrugs thereof
  • Still further preferred compounds of the invention are those of formula 1 in which R 1 , R 2 and R 3 are all methyl, R 5 is hydrogen and R 4 is alkyl or halo and prodrugs thereof
  • Preferred prodrugs of the invention are phosphate esters Particularly preferred prodrugs of the invention are dihydrogen phosphate esters
  • compounds of formula (1) can be prepared by Wittig olefin synthesis involving reaction of a phosphonium salt of formula (2) with a strong base, for example an alkyllithium such as n-butyllithium or t-butyllithium or a metal hydride such as sodium hydride in a solvent such as an ether solvent for example diethyl ether or tetrahydrofuran or in a solvent such as a hydrocarbon solvent for example toluene at a temperature of between about -100°C to about 30°C followed by treatment with an aldehyde of formula (3) in which R 6 is a protecting group, to give an intermediate of formula (4) The synthesis of compounds of formula (1) is then completed by removal of the group R 6 .
  • a strong base for example an alkyllithium such as n-butyllithium or t-butyllithium or a metal hydride such as sodium hydride in a solvent such as an ether solvent for example diethyl
  • Suitable protecting groups R 6 include trialkylsilyl, for example t- butyldimethylsilyl, and allyl
  • R 6 is a trialkylsilyl group it may be removed, for example, by treatment with a quaternary ammonium fluoride such as tetrabutylammonium fluoride in an ether solvent such as tetrahydrofuran at a temperature of about -30°C to about 40°C conveniently at or near ambient temperature
  • R 6 is an allyl group it may be removed for example by treatment with a palladium(O) complex such as tetrakis(triphenylphosphine)Pd(0) in a solvent such as a chlorinated solvent, for example dichloromethane, at a temperature of about - 40°C to about 40°C conveniently at or near ambient temperature, in the presence of an allyl scavenger such as morpholine.
  • Aldehydes of formula (3) can be prepared by any process known to a person skilled in the art.
  • an aldehyde of formula (3) can be prepared from an alcohol of formula (5) by oxidation with a suitable oxidising agent Suitable oxidising agents include the Dess-Martin reagent and manganese dioxide Alcohols of formula (5) can be prepared by application of standard methods of organic synthesis including the selective protection of phenols of formula (6).
  • alcohols of formula (5) may be prepared, for example, by treatment of a phenol of formula (6) with a strong base, for example an alkyllithium such as n-butyllithium or t-butyllithium or a metal hydride such as sodium hydride in a solvent such as an ether solvent for example diethyl ether or tetrahydrofuran or in a solvent such as a hydrocarbon solvent for example toluene at a temperature of between about -100°C to about 40°C followed by treatment with tert- butylchlorodimethylsilane.
  • a strong base for example an alkyllithium such as n-butyllithium or t-butyllithium or a metal hydride such as sodium hydride in a solvent such as an ether solvent for example diethyl ether or tetrahydrofuran or in a solvent such as a hydrocarbon solvent for example toluene at a temperature of between about
  • Phenols of formula (6) are either known or may be prepared from known compounds using standard methods of organic synthesis.
  • Compounds of formula ( 1) may also be prepared from other compounds of formula (1) by chemical modification. Examples of such chemical modifications that may be applied are standard alkylation, halogenation, oxidation and coupling reactions. These reactions may be used to add new substituents or to modify existing substituents.
  • Prodrugs of compounds of formula (1) can be prepared by any process known to a person skilled in the art. Processes for the preparation of prodrugs of compounds of formula 1 include standard acylation, sulphation and phosphorylation reactions.
  • dihydrogen phosphate esters of compounds of formula (1) can be prepared by treatment of the corresponding di-t-butylphosphate esters with an acid, for example hydrochloric acid or trifluoroacetic acid, in a solvent such as a chlorinated solvent, for example dichloromethane, at a temperature of from about -20°C to about 40°C, conveniently at room temperature.
  • Compounds according to the invention are able to destroy tumour vasculature and vasculature that has been newly formed while leaving unaffected normal, mature vasculature.
  • the ability of the compounds to act in this way may be determined by the tests described hereinafter.
  • the compounds according to the invention are thus of particular use in the prophylaxis and treatment of cancers involving solid tumours and in the prophylaxis and treatment of diseases where inappropriate angiogenesis occurs such as diabetic retinopathy, psoriasis, rheumatoid arthritis, atherosclerosis and macular degeneration.
  • compositions for the treatment of neovascularisation which compositions contain an effective amount of a cis-stilbene or prodrugs thereof as hereinbefore defined.
  • the invention also includes the use in the preparation of a composition for the treatment of neovascularisation of a cis-stilbene or prodrugs therof as hereinbefore defined.
  • compounds of the invention may be administered in combination with radiotherapy or in combination with other anti-tumour substances for example those selected from mitotic inhibitors, for example vinblastine, vincristine, vinorelbine, paclitaxel and docetaxel; platinum derivatives for example cisplatin and carboplatin; alkylating agents, for example melphalan, chlorambucil, busulphan, ifosfamide and cyclophosphamide; antimetabolites, for example methotrexate, 5-fluorouracil, cytosine arabinoside, gemcitabine and hydroxyurea; antitumour antibiotics for example bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin,mitomycin-C, dactinomycin and mithramycin ; enzymes, for example aspariginase; topoisomerase inhibitors for example etoposide,teniposide, topotecan and
  • Such combination treatment may involve simultaneous or sequential application of the individual components of the treatment.
  • the compounds according to the invention may be administered as pharmaceutical compositions selected with regard to the intended route of administration and standard pharmaceutical practice.
  • Such pharmaceutical compositions may take a form suitable for oral, buccal, nasal, topical, rectal or parenteral administration and may be prepared in a conventional manner using conventional excipients
  • the pharmaceutical compositions may take the form of tablets or capsules
  • Topical administration may be as an ointment or cream and rectal administration may be as a suppository
  • parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
  • the composition may take the form of, for example, a sterile solution, suspension or emulsion
  • the dose of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, the route of administration, the form and severity of the condition and whether the compound is to be administered alone or in combination with another drug Thus the precise dose will be determined by the administering physician but in general daily dosages may be in the range 0 001 to l OOmg/kg preferably 0 1 to lOmg/kg
  • Tumour functional vascular volume in CaNT tumour-bearing mice was measured using the fluorescent dye Hoechst 33342 according to the method of Smith et al (Brit J Cancer 57, 247-253, 1988) At least three animals were used in control and treated groups.
  • the fluorescent dye was dissolved in saline at 6.25 mg/ml and injected intravenously at 10 mg/kg 24 hours after intraperitoneal drug treatment. One minute later, animals were killed and tumours excised and frozen; 10 ⁇ m sections were cut at 3 different levels and observed under UV illumination using an Olympus microscope equipped with epifluorescence.
  • aqueous phase was extracted with diethylether (5 portions of 20ml) and the combined extracts were washed with aqueous sodium thiosulphate solution (3 portions of 10ml), water (3 portions of 10ml) and brine (2 portions of 10ml), dried (MgSO4) and concentrated under reduced pressure to give a yellow solid. Purification by chromatography on silica gel, eluting with petroleum ether / diethyl ether (50:50) gave 3-tert-butyldimethylsilyIoxy-4- methylbenzaldehyde (85mg).
  • Trifluoroacetic acid (0.22mL, 2.95mmol) was added dropwise to a stirred solution of (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl di-tcvtbutyl phosphate (401mg, 0.82mmol) and dichloromethane (16mL). The mixture was stirred at room temperature overnight. Solvent was removed in vacuo, and the residue azeotroped four times with toluene. The colourless oil was triturated with ether to give the title compound as a white solid (18 l g, 58%) m.p. 109-1 13°C.
PCT/GB2000/003067 1999-02-16 2000-08-09 New stilbenes with vascular damaging activity WO2001012579A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ517069A NZ517069A (en) 1999-08-12 2000-08-09 New stilbenes with vascular damaging activity
AU64581/00A AU779980B2 (en) 1999-02-16 2000-08-09 New stilbenes with vascular damaging activity
JP2001516880A JP2003507356A (ja) 1999-08-12 2000-08-09 血管損傷活性を有する新しいスチルベン類
CA002379544A CA2379544A1 (en) 1999-08-12 2000-08-09 New stilbenes with vascular damaging activity
EP00951727A EP1206429A2 (en) 1999-08-12 2000-08-09 Stilbenes with vascular damaging activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918912.8A GB9918912D0 (en) 1999-08-12 1999-08-12 New stilbenes with vascular damaging activity
GB9918912.8 1999-08-12

Publications (2)

Publication Number Publication Date
WO2001012579A2 true WO2001012579A2 (en) 2001-02-22
WO2001012579A3 WO2001012579A3 (en) 2001-10-11

Family

ID=10858950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003067 WO2001012579A2 (en) 1999-02-16 2000-08-09 New stilbenes with vascular damaging activity

Country Status (6)

Country Link
EP (1) EP1206429A2 (it)
JP (1) JP2003507356A (it)
CA (1) CA2379544A1 (it)
GB (1) GB9918912D0 (it)
NZ (1) NZ517069A (it)
WO (1) WO2001012579A2 (it)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068870A1 (en) * 1998-04-03 2001-01-17 Ajinomoto Co., Inc. Antitumor agents
WO2002014329A1 (en) * 2000-08-15 2002-02-21 Angiogene Pharmaceuticals Ltd. Compositions with vascular damaging activity
WO2002050007A2 (en) * 2000-12-21 2002-06-27 Cancer Research Technology Limited Substituted stilbenes, their reactions and anticancer activity
WO2004085361A1 (en) * 2003-03-26 2004-10-07 Angiogene Pharmaceuticals Limited Bioreductively activated stilbene prodrugs
EP1631540A2 (en) * 2003-12-16 2006-03-08 GTX Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
WO2009067706A1 (en) 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms
EP2348012A1 (fr) 2002-04-11 2011-07-27 Aventis Pharma S.A. Procede de preparation de combretastatine
US8039513B2 (en) 2004-07-21 2011-10-18 Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020092134A1 (en) 2018-10-29 2020-05-07 Cepheid Exponential base-3 nucleic acid amplification with reduced amplification time using nested overlapping primers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US10918735B2 (en) 2012-12-04 2021-02-16 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US11932650B2 (en) 2018-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085743B (zh) * 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
JP2011016777A (ja) * 2009-07-10 2011-01-27 Nipro Corp 新規システイン誘導体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016486A1 (en) * 1991-03-22 1992-10-01 Aston Molecules Limited Substituted diphenylethylenes and analogues or derivatives thereof
EP0641767A1 (en) * 1993-09-08 1995-03-08 Ajinomoto Co., Inc. Cytotoxic stilbene derivatives and pharmaceutical composition containing them
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
WO2000048590A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Substituted stilbene compounds with vascular damaging activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016486A1 (en) * 1991-03-22 1992-10-01 Aston Molecules Limited Substituted diphenylethylenes and analogues or derivatives thereof
EP0641767A1 (en) * 1993-09-08 1995-03-08 Ajinomoto Co., Inc. Cytotoxic stilbene derivatives and pharmaceutical composition containing them
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
WO2000048590A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Substituted stilbene compounds with vascular damaging activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. A. WOODS: "The interaction with tubulin of a series of stilbenes based on combretastatin A-4" BRITISH JOURNAL OF CANCER, vol. 71, 1995, pages 705-711, XP000978556 cited in the application *
K. OHSUMI: "Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships" JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pages 3022-3032, XP002102895 WASHINGTON US cited in the application *
M. CUSHMAN: "Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization" JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, 1991, pages 2579-2588, XP000571676 WASHINGTON US cited in the application *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068870A1 (en) * 1998-04-03 2001-01-17 Ajinomoto Co., Inc. Antitumor agents
US7655696B2 (en) 1998-04-03 2010-02-02 Ajinomoto Co., Inc. Anti-tumor composition
US7973076B2 (en) 1998-04-03 2011-07-05 Ajinomoto Co., Inc. Anti-tumor composition
EP1068870A4 (en) * 1998-04-03 2003-02-12 Ajinomoto Kk ANTITUMOR AGENTS
US6992106B2 (en) 1998-04-03 2006-01-31 Ajinomoto Co., Inc. Anti-tumor composition
WO2002014329A1 (en) * 2000-08-15 2002-02-21 Angiogene Pharmaceuticals Ltd. Compositions with vascular damaging activity
US7105501B2 (en) 2000-08-15 2006-09-12 Angiogene Pharmaceuticals Ltd. Compositions with vascular damaging activity
WO2002050007A3 (en) * 2000-12-21 2002-10-17 Cancer Res Ventures Ltd Substituted stilbenes, their reactions and anticancer activity
US8853270B2 (en) 2000-12-21 2014-10-07 University Of Salford Substituted stilbenes and their reactions
WO2002050007A2 (en) * 2000-12-21 2002-06-27 Cancer Research Technology Limited Substituted stilbenes, their reactions and anticancer activity
EP2354118A1 (fr) 2002-04-11 2011-08-10 Aventis Pharma S.A. Procédé de préparation de combretastatine
EP2348012A1 (fr) 2002-04-11 2011-07-27 Aventis Pharma S.A. Procede de preparation de combretastatine
WO2004085361A1 (en) * 2003-03-26 2004-10-07 Angiogene Pharmaceuticals Limited Bioreductively activated stilbene prodrugs
EP1631540A2 (en) * 2003-12-16 2006-03-08 GTX Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
EP1631540A4 (en) * 2003-12-16 2006-10-04 Gtx Inc PRODRUGS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD OF USE THEREOF
US7595402B2 (en) 2003-12-16 2009-09-29 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US8039513B2 (en) 2004-07-21 2011-10-18 Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Cis-1,2-substituted stilbene derivatives and their use in preparation of drugs for treatment and/or prevention of diabetes
WO2009067706A1 (en) 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms
US9040500B2 (en) 2007-11-21 2015-05-26 Oxigene, Inc. Method for treating hematopoietic neoplasms
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
US10918735B2 (en) 2012-12-04 2021-02-16 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11932650B2 (en) 2018-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
WO2020092134A1 (en) 2018-10-29 2020-05-07 Cepheid Exponential base-3 nucleic acid amplification with reduced amplification time using nested overlapping primers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Also Published As

Publication number Publication date
EP1206429A2 (en) 2002-05-22
CA2379544A1 (en) 2001-02-22
GB9918912D0 (en) 1999-10-13
JP2003507356A (ja) 2003-02-25
NZ517069A (en) 2004-04-30
WO2001012579A3 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
RU2232021C2 (ru) Применение производных колхинола в качестве средств, повреждающих сосуды
WO2001012579A2 (en) New stilbenes with vascular damaging activity
EP1896391B1 (en) Combretastatin analogs with tubulin binding activity
EP1751128B1 (en) Chromene-derivatives with anti-tubulin and vascular targeting activity
CZ703288A3 (en) Benzocycloheptene derivatives and their use as a medicament
JP2010138192A (ja) 化学療法剤、化学予防剤、および抗脈管形成剤としての新規なフラバノイドおよびカルコン
US7265136B1 (en) Substituted stilbene compounds with vascular damaging activity
JP2004505888A (ja) チューブリン結合リガンドおよび対応するプロドラッグ構造
EP1311514B1 (en) Compositions with vascular damaging activity
JP4780885B2 (ja) 正常細胞を化学療法剤の細胞毒性から保護するための方法
AU779980B2 (en) New stilbenes with vascular damaging activity
WO2015154716A1 (zh) 菲罗啉膦酸类衍生物及其制备方法和应用
JPH0559117B2 (it)
US20050245489A1 (en) Chromene-containing compounds with anti-tubulin and vascular targeting activity
Brondani et al. Synthesis and Antitumour Activity of the Primin (2-methoxy-6-n-pentyl-1, 4-benzoquinone) and Analogues
JPS6144836A (ja) 置換スチレン誘導体
CA3191119A1 (en) Antitumoral ascorbic acid esters
MXPA99011154A (es) Uso de derivados colquinol como agentes dañinos vasculares

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 517069

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2379544

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 64581/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000951727

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10049248

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000951727

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 517069

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517069

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 64581/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000951727

Country of ref document: EP